- PPD: Sage plans to initiate a Phase 2 clinical program for SAGE-217 in PPD based on positive results to date from the SAGE-547 PPD clinical program. The Phase 2a multi-center, double-blind, placebo-controlled, randomized trial will evaluate the efficacy, safety, tolerability, and pharmacokinetics of SAGE-217 in the treatment of patients with PPD.
- MDD: Sage plans to initiate a two-part Phase 2 clinical trial of SAGE-217 in MDD. Part A of the Phase 2 trial will be an open-label, proof-of-concept study which, if positive, may lead to a larger randomized, placebo-controlled Phase 2 trial.
Slingshot members are tracking this event:
SAGE Plans to Initiate Phase 2 Trials for SAGE 217 (Essential Tremors and Orphan Epilepsies) 2nd Half of 2016
- Source Link:
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Dec 13, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Sage-217, Phase 2 Initiation